MRNA Stock Down -19% after 5-Day Loss Streak
Moderna (MRNA) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -19% return. The company has lost about $2.0 Bil in value over the last 5 days, with its current market capitalization at about $11 Bil. The stock remains 33.6% below its value at the end of 2024. This compares with year-to-date returns of 6.1% for the S&P 500.
MRNA develops mRNA-based therapeutics and vaccines for infectious, immuno-oncology, rare, cardiovascular, and autoimmune diseases with 44 development programs, including 26 clinical trials across seven modalities. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell MRNA.
Comparing MRNA Stock Returns With The S&P 500
The following table summarizes the return for MRNA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MRNA | S&P 500 |
|---|---|---|
| 1D | -6.6% | -1.6% |
| 5D (Current Streak) | -19.2% | -2.4% |
| 1M (21D) | -8.8% | 0.2% |
| 3M (63D) | 2.1% | 11.3% |
| YTD 2025 | -33.6% | 6.1% |
| 2024 | -58.2% | 23.3% |
| 2023 | -44.6% | 24.2% |
| 2022 | -29.3% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: MRNA Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 13 S&P constituents with 3 days or more of consecutive gains and 188 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 1 | 89 |
| 4D | 10 | 33 |
| 5D | 2 | 49 |
| 6D | 0 | 4 |
| 7D or more | 0 | 13 |
| Total >=3 D | 13 | 188 |
Key Financials for Moderna (MRNA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $6.8 Bil | $3.2 Bil |
| Operating Income | $-4.2 Bil | $-3.9 Bil |
| Net Income | $-4.7 Bil | $-3.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $956.0 Mil | $107.0 Mil |
| Operating Income | $-1.2 Bil | $-1.0 Bil |
| Net Income | $-1.1 Bil | $-971.0 Mil |
The losing streak MRNA stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.